Related Experiment Videos
Gene identification in Alzheimer's disease
1Box 2900, Department of Medicine (Neurology), Duke University Medical Center, Durham, NC 27710, USA. saund005@mc.duke.edu
Pharmacogenomics
|September 6, 2001
Summary
Alzheimer's disease (AD) genetics involves rare early-onset genes and common late-onset susceptibility genes like APOE. Identifying more genes aids understanding AD pathogenesis and developing pharmacogenomic treatments.
Area of Science:
- Genetics
- Neuroscience
- Pharmacogenomics
Background:
- Alzheimer's disease (AD) is the leading cause of dementia in older adults.
- Familial, early-onset AD is linked to mutations in APP, PSEN1, and PSEN2 genes, accounting for less than 2% of cases.
- Late-onset AD, over 50% of cases, is associated with the apolipoprotein E (APOE) gene on chromosome 19.
Purpose of the Study:
- To review the genetic basis of Alzheimer's disease and related dementias.
- To highlight the role of susceptibility genes, such as APOE, in late-onset AD.
- To emphasize the potential of pharmacogenomics in understanding disease mechanisms and identifying drug targets.
Main Methods:
- Review of identified genes associated with early-onset and late-onset Alzheimer's disease.
- Discussion of whole genome scans for identifying novel susceptibility regions.
- Exploration of pharmacogenomic tools for gene-to-function studies.
Main Results:
- Three genes (APP, PSEN1, PSEN2) identified for early-onset familial AD.
- APOE gene identified as a major susceptibility factor for late-onset AD.
- Promising chromosomal regions (6, 9, 10, 12) identified for additional susceptibility genes.
Conclusions:
- Genetic discoveries are crucial for elucidating Alzheimer's disease pathogenesis.
- Pharmacogenomics offers a rapid approach to study gene function and identify therapeutic targets.
- Understanding genetic factors is key for developing targeted drug selection and pharmacogenetic strategies.